Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma

Leukemia

Volumn 23, Issue 3, 2009, Pages 585-590

  Mao, X ^a   Li, X ^a   Sprangers, R ^b   Wang, X ^a   Venugopal, A ^a   Wood, T ^a,b   Zhang, Y ^a,b   Kuntz, D A ^a   Coe, E ^a   Trudel, S ^a,b   Rose, D ^a,b   Batey, R A ^b   Kay, L E ^b   Schimmer, A D ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; CLIOQUINOL; PROTEASOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; MOUSE; MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; UBIQUITINATION;

EID: 62549083952     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.232     Document Type: Article

References (8)

1. Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 1995; 268: 533-539.
2. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
3. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867-4874.
4. Groll M, Berkers CR, Ploegh HL, Ovaa H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 2006; 14: 451-456.
5. Chen D, Cui QC, Yang H, Barrea RA, Sarkar FH, Sheng S et al. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Res 2007; 67: 1636-1644.
6. Sprangers R, Li X, Mao X, Rubinstein JL, Schimmer AD, Kay LE. TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors. Biochemistry 2008; 112: 760-769.
7. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch Neurol 2003; 60: 1685-1691.
8. Tateishi J. Subacute myelo-optico-neuropathy: Clioquinol intoxication in humans and animals. Neuropathology 2000; 20 (Suppl): S20-S24.